Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valneva ( (VALN) ) has issued an update.
On August 12, 2025, Valneva SE reported its financial results for the first half of 2025, showing a significant increase in total revenues to €97.6 million, up from €70.8 million in the same period of 2024. Despite a net loss of €20.8 million, the company achieved a substantial reduction in operating cash burn and confirmed its financial outlook for 2025. Key developments included a new supply contract with the U.S. Department of Defense and marketing authorizations for its chikungunya vaccine in the UK and Brazil, highlighting strategic progress in expanding its vaccine offerings and market reach.
The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score is driven by its challenging financial performance and valuation concerns, despite strong technical indicators and positive revenue growth highlighted in the earnings call. The company’s financial health needs improvement, and the stock’s bullish momentum may face resistance due to overbought conditions.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company based in France, focusing on developing and commercializing vaccines for infectious diseases. The company’s portfolio includes vaccines for Japanese encephalitis, cholera, and chikungunya, and it operates in various markets, including partnerships for distribution in Germany.
Average Trading Volume: 55,813
Technical Sentiment Signal: Buy
Current Market Cap: $719.3M
Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.